|1.||Erez, Offer: 3 articles (04/2010 - 01/2008)|
|2.||Kusanovic, Juan Pedro: 3 articles (04/2010 - 01/2008)|
|3.||Mazaki-Tovi, Shali: 3 articles (04/2010 - 01/2008)|
|4.||Hassan, Sonia S: 3 articles (04/2010 - 01/2008)|
|5.||Romero, Roberto: 3 articles (04/2010 - 01/2008)|
|6.||Gotsch, Francesca: 3 articles (04/2010 - 01/2008)|
|7.||Vaisbuch, Edi: 3 articles (04/2010 - 01/2008)|
|8.||Dua, Kamal: 2 articles (12/2010 - 10/2010)|
|9.||Pabreja, Kavita: 2 articles (12/2010 - 10/2010)|
|10.||Gomez, Ricardo: 2 articles (04/2010 - 01/2008)|
07/01/1995 - "The purpose of this retrospective study was to elucidate 1) which subgroups are prone to have ischemic cerebrovascular disease (CVD) among patients with atrial fibrillation (Af), 2) vulnerable period of CVD after the diagnosis of chronic Af and 3) the clinical efficacy of antiplatelet therapy in chronic nonvalvular Af patients. "
05/01/2001 - "The study group consisted of 77 patients (M/F = 65/12, age 66 +/- 12 years) with frequent episodes of PAF; we analyzed: 1) 15 cycle lengths of electrical activity before the onset of atrial fibrillation (AF); 2) coupling interval (CI) of the first ectopic beat just before the initiation of AF; and 3) the prematurity of an ectopic beat (prematurity index [PI] = CI/mean of preceding 15 cycle lengths). "
07/01/2011 - "Ablation is more successful for patients with paroxysmal atrial fibrillation (AF1) than for those with persistent (AF2) or longstanding persistent AF (AF3). "
04/07/2004 - "The aim of this study was to compare the relative cost of a transesophageal echocardiography (TEE)-guided strategy versus conventional strategy for patients with atrial fibrillation (AF) >2 days duration undergoing electrical cardioversion over an eight-week period. "
12/19/2005 - "Among several catheter-based strategies for curing atrial fibrillation (AF), 2 approaches have emerged as dominant strategies in current clinical practice: ostial segmental disconnection of all pulmonary veins (PVs) from the adjacent atrial tissue and circumferential PV ablation, first reported by our laboratory in Milan. "
03/01/2001 - "In conclusion, AF-2 reduced HL-60 adhesion to endothelial cells, suggesting that it reduces inflammation by blocking leukocyte trafficking and the subsequent eicosanoid production."
12/01/2010 - "AF2 was shown to be significantly (p < 0.05) more effective in inhibiting hyperalgesia associated with inflammation, compared to AF3 and AF7. "
11/01/2008 - "The purpose of this study was to: (1) determine whether CXCL13 is present in maternal serum, umbilical cord blood, and amniotic fluid (AF); (2) to determine if AF concentration changes with intra-amniotic infection/inflammation (IAI); and (3) to localize the production of CXCL13 in chorioamniotic membranes and umbilical cord. "
06/01/1994 - "The effect of Factor AF2 (AF2), a standardized fraction of peptides with a molecular weight of < 10,000 Dalton obtained from livers and spleens of newborn lambs, on the differentiation of human monocyte-derived macrophages was studied, in view of the central role played by these cells in inflammation and tumor cytotoxicity. "
06/01/1989 - "The rate of binding of a fluorescent probe for hypoxia, AF-2, is dependent upon cell temperature as well as oxygenation. "
03/01/1987 - "Enhanced MISO binding by AF-2 occurred for both ring-labeled and side chain-labeled MISO, was proportional to AF-2 concentration, and was greatest under anoxia. "
01/01/1983 - "Although 4NQO is a far more potent single cell mutagen than AF-2 for equimolar exposures of single cells, the internal cells of spheroids exposed to 7.5 micrograms/ml of either agent under hypoxia were more readily mutated by AF-2 than by 4NQO."
01/01/1983 - "However, 4NQO is metabolized under oxic as well as hypoxic conditions, while AF-2 is reduced predominantly under hypoxia. "
04/01/1978 - "Human fibroblasts were more sensitive to AF 2 both under aerobic conditions and in hypoxia than were V 79 cells under similar conditions. "
|4.||Hypertension (High Blood Pressure)
08/15/2009 - "Among AD patients there were 5 with arterial hypertension (AH), 3 with atrial fibrillation (AF), 2 with diabetes mellitus (DM), 6 with hyper lipidemia and 1 smoker. "
11/01/2015 - "We describe here the case of a 55-year-old woman with primary biliary cirrhosis who presented a first-detected, symptomatic AF 2 h after azathioprine therapy which resolved after discontinuation of the drug with no predisposing factors for supraventricular arrhythmias (systemic hypertension, diabetes or coronary artery disease). "
05/01/2010 - "Dexamethasone treatment is effective in controlling the premature pubarche, hypoglycemia, hypertension, and hypokalemia in this child case, wherein arginine 714 plays a key role in the proper formation of the ligand-binding pocket and the AF-2 surface of the GR alpha LBD."
|5.||Melanoma (Melanoma, Malignant)
|6.||Estrogen Receptor alpha
|7.||DNA (Deoxyribonucleic Acid)
|8.||butyl phosphorotrithioate (DEF)
|10.||Tretinoin (Retinoic Acid)
|2.||Electric Countershock (Cardioversion)
|4.||Transplantation (Transplant Recipients)
|5.||Drug Therapy (Chemotherapy)